Trials — ASH 2026
The primary artifact of this vault: one Markdown file per trial / readout. ASH 2026 is a clinical-readout meeting, so the unit of analysis is the trial — not the speaker, not the tool, not the company. Same per-trial schema as ASCO 2026 and ESMO 2026; ASH adds an explicit cell-and-gene-therapy sub-axis and a non-malignant heme sub-axis.
Status: Template + master index. Per-trial pages will be populated in two waves: (1) regular abstracts upon Blood-supplement release on Nov 4, 2026, 9:00 AM ET; (2) Late-Breaking Abstracts on ~Nov 24, 2026, 12:00 noon ET. Pre-meeting stubs flagged *expected, subject to embargo* are sourced from company toplines, EHA 2026 mid-year readouts, ASCO 2026 heme subset, and analyst preview pieces; numbers can shift on the actual abstract reveal.
Per-trial template
Each trial file (e.g., frontmind-update.md) follows this schema. Copy and fill:
# <Trial acronym / name> — <Drug regimen, indication, line>
> **Abstract:** <abstract #, e.g., LBA-1 / Plenary #6 / Abstract 234> · **Session:** <session name, date, time CT, hall> · **Embargo:** <date>
## At a glance
- **Sponsor:** <pharma / cooperative group>
- **PI / presenter:** <name, institution>
- **NCT ID:** <NCTxxxxxxxx>
- **Phase:** <1 / 1b / 2 / 2-3 / 3 / pivotal / registry>
- **Design:** <arms, randomization, blinding>
- **N:** <enrolled / analyzed>
- **Primary endpoint(s):** <PFS / OS / EFS / CR rate / MRD-neg / VOC-free / FVIII expression>
- **Comparator:** <SOC / placebo / active comparator / historical>
- **Indication:** <heme disease, subtype, biomarker / cytogenetic selection>
- **Line:** <frontline / 1L / 2L / 3L+ / maintenance / post-transplant / post-CAR-T>
## Headline result
<One paragraph. Numbers + HR + p-value if known. If pre-embargo, mark
`*expected per <company> topline <date>*` or `*pre-embargo per <analyst source>*`
or `*EHA 2026 readout, ASH 2026 update expected*`.>
## Mechanism / class
<Drug class, target, prior approvals if any. For CAR-T: construct details (costim
domain, CD-target, manufacturing). For bispecifics: format (IgG-like, BiTE,
DART). For gene therapy: vector + payload. Cross-link to related AACR
mechanism sessions.>
## Discussant takeaway
<Named discussant + key framing once known. ASH discussant identity is itself
a signal — senior figures in the relevant disease group set the post-meeting
narrative.>
## Practice-changing?
<Yes / no / pending, with rationale: NCCN guideline implications, FDA filing path,
unmet need, prior SOC. For non-malignant heme: NCCN-equivalent ASH guideline path.>
## Cross-links
- **AACR 2026:** <related mechanism / poster / session, if applicable>
- **AACR 2025:** <prior-year mechanism work>
- **ASCO 2026:** <heme readout earlier in the year, if applicable>
- **EHA 2026:** <mid-year European readout, if applicable>
- **ESMO 2026:** <if heme readout was presented there>
- **Other ASH 2026 trials:** <same class, same disease>
- **JPM 2026 / 2027:** <sponsor presentation / deal>
## Sources
- ASH abstract (Blood supplement): <URL or "pending Nov 4 release">
- Company press release: <URL>
- Trade-press recap: <OncLive / ASH Clinical News / Healio / ASCO Post URL>
- ClinicalTrials.gov: <NCT URL>
Master trial index (pre-meeting watch list)
Pre-meeting shortlist for stub creation. All entries below are pre-abstract-release, sourced from company pipelines + AACR 2026 mechanism sessions + EHA 2025 / ASH 2025 prior-year readouts + analyst preview pieces — to be reconciled with the Nov 4, 2026 abstract drop and the late-November LBA release. Result column entries marked italic are speculative / not yet disclosed.
Lymphoma — DLBCL + bispecifics
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status (pre-abstract-release) |
| EPCORE NHL-2 / NHL-3 follow-up |
Genmab / AbbVie |
r/r DLBCL + 1L combinations |
1b/2 / 3 |
PFS / CR / durability |
3+ yr durability of epco mono; 1L combination signal |
| GO29781 / glofit + Pola-R-CHP |
Roche |
1L DLBCL high-IPI |
3 |
PFS / EFS |
Topline tracking; possible practice-changing |
| MajesTEC analog in DLBCL |
various |
r/r DLBCL post-CAR-T |
2 |
ORR / CR |
Sequencing question — bispecific after CAR-T failure |
| frontMIND long-term follow-up |
Incyte / MorphoSys |
1L DLBCL high-IPI (tafa+lena+R-CHOP) |
3 |
OS / PFS update |
ASCO 2026 LBA7000 PFS+; ASH update expected |
| CD20×CD3 head-to-head registry data |
multi-sponsor |
r/r DLBCL real-world |
obs |
OS / ORR by class |
CIBMTR + ASH-flow registries |
Lymphoma — CLL + indolent
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| BRUIN CLL-321 / pirtobrutinib |
Lilly |
covalent-BTKi-resistant CLL |
3 |
PFS |
Pivotal update; possibly Plenary candidate |
| TRANSCEND CLL 004 follow-up |
BMS |
r/r CLL liso-cel |
1/2 |
DOR / OS |
2-3 yr durability |
| Venetoclax fixed-duration combos |
AbbVie |
frontline CLL |
3 |
MRD-neg / PFS |
MAJIC, CLL17, others |
Myeloma — CAR-T + bispecifics
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| CARTITUDE-5 / -6 cilta-cel |
J&J / Legend |
NDMM / 1L MM |
3 |
PFS / MRD |
Pivotal frontline data expected |
| KarMMa-9 ide-cel |
BMS / 2seventy |
NDMM |
3 |
PFS |
Frontline ide-cel pivot |
| MajesTEC-3 / -5 teclistamab |
J&J |
r/r MM + 1L combos |
3 |
PFS |
ASCO 2026 follow-up; ASH long-term |
| MonumenTAL-3 talquetamab |
J&J |
r/r MM 1–3L |
3 |
PFS |
Pivotal |
| RedirecTT-1 / -2 |
J&J |
EMD MM dual bispecific |
1b/2 |
ORR |
Dual bispecific (BCMA + GPRC5D) |
| Allogeneic BCMA CAR-T |
Allogene / Caribou / others |
r/r MM |
1 |
safety + ORR |
Class watch |
Acute leukemias — AML + ALL
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| Revumenib AUGMENT-101 follow-up + combos |
Syndax |
r/r KMT2A-r / NPM1-mut AML |
1/2 + combos |
CR / MRD |
Post-approval real-world + combos with ven/aza |
| Ziftomenib KOMET-001 / -007 / -008 |
Kura |
r/r NPM1-mut AML + frontline combos |
2 / 3 |
CR / OS |
Post-approval + frontline pivot |
| Venetoclax maintenance |
AbbVie |
post-induction AML |
3 |
RFS / OS |
VIALE-M, others |
| FLT3 inhibitors evolution |
various |
FLT3-mut AML |
3 |
OS |
Gilteritinib, quizartinib follow-up; new TKIs |
| Frontline IDH inhibitors |
Servier / others |
IDH1/2-mut AML |
3 |
EFS / OS |
Ivosidenib, enasidenib, olutasidenib frontline |
| CD19 / CD22 CAR-T in ALL |
Kite / Novartis / academic |
r/r B-ALL |
3 + registry |
EFS / OS |
Adult ALL pivots + pediatric updates |
MDS / MPN
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| Imetelstat post-approval |
Geron |
lower-risk MDS, transfusion-dependent |
reg / 4 |
TI rate |
Post-IMerge real-world |
| COMMANDS follow-up |
BMS / Acceleron |
lower-risk MDS ESA-naive luspatercept |
3 |
TI rate |
Long-term durability |
| IDH inhibitors in MDS |
Servier |
IDH-mut MDS |
2/3 |
response |
Frontline + post-HMA |
| Momelotinib / pacritinib MF |
GSK / Sobi |
myelofibrosis |
3 / 4 |
symptom + anemia |
Post-approval real-world |
Cell and gene therapy — durability + access
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| Exa-cel / Casgevy 3+ yr follow-up |
Vertex / CRISPR |
sickle cell + beta-thalassemia |
reg / 4 |
VOC-free / TI |
Post-approval durability + pediatric |
| Lovo-cel / Lyfgenia 3+ yr follow-up |
bluebird bio |
sickle cell |
reg / 4 |
VOC-free |
Post-approval; second-malignancy reporting |
| In-vivo base / prime editing for SCD |
Beam / Editas / others |
sickle cell (early phase) |
1 |
safety + edit efficiency |
Class watch — next gen |
| Roctavian (val-rox) long-term |
BioMarin |
hemophilia A |
reg / 4 |
FVIII expression curve |
2–4 yr durability |
| Hemgenix (etranadez) long-term |
CSL |
hemophilia B |
reg / 4 |
FIX expression curve |
2–4 yr durability |
| CAR-T 5-yr durability (axi-cel, liso-cel, cilta-cel, ide-cel) |
Kite / BMS / J&J |
r/r LBCL + MM |
reg / 4 |
DOR / PFS / SPM |
The "CAR-T tail" — long-term curves + second-primary-malignancy |
Non-malignant heme
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| Mim8 / next-gen FVIIIa-mimetic |
Novo Nordisk |
hemophilia A (with / without inhibitors) |
3 |
bleed rate |
Post-FRONTIER pivot data |
| Concizumab / fitusiran follow-up |
Novo / Sanofi |
hemophilia A/B with inhibitors |
3 |
bleed rate |
Real-world + long-term |
| TTP / iTTP cap / rituximab combos |
Sanofi / academic |
iTTP |
3 / registry |
exacerbation rate |
Caplacizumab follow-up |
| Aplastic anemia frontline horse-ATG + eltrombopag |
NIH / academic |
severe AA |
3 |
response |
Long-term + transplant comparison |
| PNH C5 vs C3 inhibitor head-to-heads |
Alexion / Novartis / Apellis |
PNH |
3 |
hemoglobin / TI |
Pegcetacoplan, iptacopan, danicopan combos |
Cross-cutting themes (for themes.md)
To synthesize across trials/ once populated:
- The "CAR-T tail" hardens. 5-yr durability curves for axi-cel, liso-cel, cilta-cel, ide-cel; SPM signal in FDA reporting; real-world vs pivotal-trial gap; sequencing after CAR-T failure.
- Bispecifics + CAR-T compete and combine. DLBCL: bispecific-after-CAR-T as standard salvage. MM: bispecific-after-CAR-T vs CAR-T-after-bispecific sequencing data. Class read-through to solid-tumor T-cell engagers (DLL3, B7-H3 — cross-link to lung / SCLC at ASCO).
- Menin / IDH / FLT3 mature in AML. Revumenib and ziftomenib post-approval; combinations with ven/aza, FLT3, IDH; frontline pivots beginning. Cross-link to AACR 2026 menin / leukemia mechanism sessions.
- Gene therapy for SCD — durability + access. Casgevy / Lyfgenia 3+ yr data; pediatric pivots; in-vivo next-gen approaches; payer access bottlenecks become the practical-care narrative.
- Hemophilia gene therapy — long-term FVIII / FIX expression decay. Roctavian and Hemgenix 2–4 yr curves define the durability ceiling; non-factor competitor data (Mim8, fitusiran) frame the alternative.
- MDS / lower-risk MDS becomes a structured space. Imetelstat + luspatercept + IDH inhibitors carve up frontline; IPSS-M-guided transplant decisions mature.
- AACR ↔ ASH mechanism-to-clinic continuity. Each ASH practice-changing trial traces to a 1–3 year prior AACR mechanism session (menin biology, CAR-T construct engineering, bispecific format, base-editing platform). Map the lineage in
themes.md.